openPR Logo
Press release

Myasthenia Gravis Disease Market Size Worth $2,538.6 Million By 2026 | Leading Companies are Alexion Pharmaceutical, Avadel Pharmaceuticals, CSL Behring, Grifols S.A., Novartis AG and others.

03-27-2019 11:24 AM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

Myasthenia Gravis Disease Market

Myasthenia Gravis Disease Market

The myasthenia gravis disease market report adds detailed competitive landscape of the global market. It includes company market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the global myasthenia gravis disease market based on product segment, technology segment, end user segment and region.

The global Myasthenia Gravis Disease Market is anticipated to exceed USD 2,538.6 Million by 2026 according to a new research published by Polaris Market Research. In 2017, the diagnosis segment dominated the global market, in terms of revenue.

Request for sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/request-for-sample

Myasthenia gravis disease is characterized by rapid fatigue and weakness of any muscles under person’s voluntary control. Though myasthenia gravis can affect people of any age, it’s more common in women younger than 40 and in men older than 60. In General, myasthenia gravis disease is caused by a breakdown in the normal communication between muscles and nerves. There is no accurate cure for MG disease, however, appropriate and early treatment can help to control symptoms, such as double vision, difficulties with speech, chewing, swallowing and breathing, weakness of arm or leg muscles, and drooping of eyelids.

The global Myasthenia Gravis Disease market is majorly driven by the need to prevent declining quality of life owing to myasthenia gravis disease. Moreover, growing R&D initiatives for novel therapies are another factor boosting the market growth. In addition, key players are also involved in innovative research to launch the affordable therapeutics for such disease. However, the unfamiliarity with early symptoms as well as signs and high cost associated with the treatment are factors hampering the market growth.

Browse summary of this report with TOC @ https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market

The global Myasthenia Gravis Disease Market is segmented on the basis of diagnosis, treatment, end-user, and region. On the basis of diagnosis, the market is categorized into Imaging, Blood Tests, Electrodiagnostic, and Edrophonium Test. The imaging segment is further bifurcated into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others. On the basis of treatment, the market is segmented into Medication, Surgery, and HSCT. The end-user is further segmented in to Hospitals, Clinics, and Academic Research Institutes.

Geographically, North America accounted for the largest share in the global Myasthenia Gravis Disease Market in 2017. The major factors accounted for the high market growth includes high occurrence of disease such in North America. Moreover, Asia Pacific is estimated to generate the lucrative market growth during the forecast period. Growing initiatives by government and private organizations for generating novel control treatment are factors estimated to propel the myasthenia gravis disease market growth in Asia Pacific. In addition, increasing awareness about neuromuscular disorders and vast improvement are boosting the market growth in APAC.

The leading companies profiled in the Myasthenia Gravis Disease Market report:

• Alexion Pharmaceutical Inc.
• Avadel Pharmaceuticals plc
• CSL Behring
• Grifols S.A.
• Baxter International Inc.
• Shire plc
• Novartis AG
• F. Hoffmann-La Roche AG
• Takeda Pharmaceutical Company Limited
• Valeant Pharmaceuticals International Inc.

Inquire before-buying @ https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/inquire-before-buying

Some points from TOC:

Chapter 1. Overview and Scope

1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-away
1.5. Stakeholders

Chapter 2. Executive Summary

2.1. Market Definition
2.2. Market Segmentation

Chapter 3. Myasthenia Gravis Disease Market Insights

3.1. Myasthenia Gravis Disease Therapies – Industry snapshot
3.2. Myasthenia Gravis Disease Therapies - Ecosystem analysis
3.3. Myasthenia Gravis Disease Market Dynamics
3.3.1. Myasthenia Gravis Disease Therapies – Market Forces
3.3.1.1. Myasthenia Gravis Disease Market Driver Analysis
3.3.1.2. Myasthenia Gravis Disease Market Restraint/Challenges analysis
3.3.1.3. Myasthenia Gravis Disease Market Opportunity Analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Myasthenia Gravis Disease Market PEST Analysis, 2017
3.6. Myasthenia Gravis Disease Market Value Chain Analysis
3.7. Myasthenia Gravis Disease Therapies Industry Trends
3.8. Competitive Ranking Analysis

Chapter 4. Myasthenia Gravis Disease Market Size and Forecast, 2017-2026 by Diagnosis

4.1. Key Findings
4.2. Imaging
4.2.1. X-ray
4.2.2. Computed Tomography (CT)
4.2.3. Magnetic Resonance Imaging (MRI)
4.2.4. Others
4.3. Blood Tests
4.4. Electrodiagnostic
4.5. Edrophonium Test

Chapter 5. Myasthenia Gravis Disease Market Size and Forecast, 2017-2026 by Treatment

5.1. Key Findings
5.2. Medication
5.3. Surgery
5.4. HSCT

Chapter 6. Myasthenia Gravis Disease Market Size and Forecast, 2017-2026 by End User

6.1. Key Findings
6.2. Hospitals
6.3. Clinics
6.4. Academic Research Institutes

Check for discount @ https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us

Mr. Rohit
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myasthenia Gravis Disease Market Size Worth $2,538.6 Million By 2026 | Leading Companies are Alexion Pharmaceutical, Avadel Pharmaceuticals, CSL Behring, Grifols S.A., Novartis AG and others. here

News-ID: 1674362 • Views:

More Releases from Polaris Market Research & Consulting

Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of 5.2%
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of …
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors. Market at a Glance In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. It
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 Billion by 2034, Growing at a CAGR of 7.5%
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 …
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape. According to the findings, the market stood at 3.82 billion in 2024 and is expected to
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expanding at a CAGR of 6.8%
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin …
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape. According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billion
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2034, Growing at a CAGR of 7.44%
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 …
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape. According to the findings, the market stood at 31.67 billion in 2024 and is expected to reach

All 5 Releases


More Releases for Myasthenia

Myasthenia Gravis (MG) Treatment Market: Insights and Trends
The Global Myasthenia Gravis (MG) Treatment Market is experiencing notable growth, driven by increasing awareness of the disease and advancements in treatment options. Myasthenia Gravis is a chronic autoimmune disorder that leads to varying degrees of muscle weakness, and effective management is crucial for improving patient quality of life. With ongoing research and development in treatment modalities, the market is poised for significant expansion over the coming years. Market Size and Growth: The
Myasthenia Gravis Market | Rising Prevalence Of Neuromuscular Disorders
According to Precision Business Insights (PBI), the latest report, the Myasthenia Gravis market is expected to be valued at USD 1,734.6 million in 2022, growing at an 8.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global Myasthenia Gravis market increasing prevalence of neuromuscular disorders, and rising awareness about effective treatment. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/myasthenia-gravis-market/ Medication Segment to Dominate the Myasthenia
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles. Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report with TOC
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report with TOC
Global Myasthenia Gravis Industry Analysis By Geography
Stratistics MRC's Myasthenia Gravis Market report explains company profiling, key segments, market trends, top players and regional, country-level segments. Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Browse complete "Myasthenia Gravis Market" report with TOC @